Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah G. Brovero, G. Brett Moreau, Anjali Sengar, Crystal Richardson, Sayeh Agah, Anna Pomés, Peter M. Kasson, Mark A. Tomai, Christopher B. Fox, William A. Petri
Abstract
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
Topics & Concepts
AdjuvantClearanceVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyMedicineCoronavirus disease 2019 (COVID-19)Spike ProteinNeutralizing antibodyImmunologyVirusPathologyInfectious disease (medical specialty)DiseaseUrologySARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesBacterial Infections and Vaccines